tradingkey.logo

Impact Biomedical Inc

IBO
查看详细走势图
0.511USD
-0.051-9.03%
收盘 12/24, 13:00美东报价延迟15分钟
6.23M总市值
亏损市盈率 TTM

Impact Biomedical Inc

0.511
-0.051-9.03%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-9.03%

5天

+16.11%

1月

+18.84%

6月

-39.17%

今年开始到现在

-64.76%

1年

-64.27%

查看详细走势图

TradingKey Impact Biomedical Inc股票评分

单位: USD 更新时间: 2025-10-27

操作建议

当前估值合理,机构持股占比非常高,目前股价在压力位和支撑位之间,可以做区间波段操作。

Impact Biomedical Inc评分

相关信息

行业排名
305 / 501
全市场排名
591 / 4682
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 0 位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Impact Biomedical Inc亮点

亮点风险
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
利润高增长
公司净利润处于行业前列,最新年度总收入0.00美元
估值高估
公司最新PE估值-0.17,处于3年历史高位
机构加仓
最新机构持股508.04K股,环比增加15.77%

Impact Biomedical Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Impact Biomedical Inc简介

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
公司代码IBO
公司Impact Biomedical Inc
CEOHeuszel (Frank D)
网址https://www.impactbiomedinc.com/

常见问题

Impact Biomedical Inc(IBO)的当前股价是多少?

Impact Biomedical Inc(IBO)的当前股价是 0.511。

Impact Biomedical Inc的股票代码是什么?

Impact Biomedical Inc的股票代码是IBO。

Impact Biomedical Inc股票的52周最高点是多少?

Impact Biomedical Inc股票的52周最高点是6.170。

Impact Biomedical Inc股票的52周最低点是多少?

Impact Biomedical Inc股票的52周最低点是0.362。

Impact Biomedical Inc的市值是多少?

Impact Biomedical Inc的市值是6.23M。

Impact Biomedical Inc的净利润是多少?

Impact Biomedical Inc的净利润为-24.71M。

现在Impact Biomedical Inc(IBO)的股票是买入、持有还是卖出?

根据分析师评级,Impact Biomedical Inc(IBO)的总体评级为--,目标价格为--。

Impact Biomedical Inc(IBO)股票的每股收益(EPS TTM)是多少

Impact Biomedical Inc(IBO)股票的每股收益(EPS TTM)是-3.932。
KeyAI